Antiviral phosphoramidates

A compound according to formula I

• wherein:
• R1 is hydrogen or aryl wherein said aryl is phenyl or naphthyl optionally substituted with one to three substituents independently selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, halogen, C1-6 haloalkyl, —N(R1a)2, C1-6 acylamino, —NHSO2C1-6 alkyl, —SO2N(R1a)2, —SO2C1-6 alkyl, COR1b, nitro and cyano;
• R1a is independently hydrogen or C1-6 alkyl;
• R1b is —OR1a or —N(R1a)2;
• R2a and R2b are (i) independently selected from the group consisting of hydrogen, C1-10 alkyl, —(CH2)rNR1a2, C1-6 hydroxyalkyl, —CH2SH, —(CH2)2S(O)pMe, —(CH2)3NHC(═NH)NH2, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, —(CH2)mCOR1b, aryl and aryl C1-3 alkyl, said aryl groups optionally substituted with a group selected from the group consisting of hydroxyl, C1-10 alkyl, C1-6 alkoxy, halogen, nitro and cyano,;
• (ii) R2a is hydrogen and R2b and R4 together are (CH2)3;
• (iii) R2a and R2b together are (CH2)n;
• or, (iv) R2a and R2b both are C1-6 alkyl;
• R3 is hydrogen, C1-10 alkyl, C1-10 haloalkyl, aryl or aryl-C1-3 alkyl wherein said aryl is phenyl;
• R4 is hydrogen, C1-3 alkyl, or R2b and R4 together are (CH2)3;
• R5 is azide, C≡CH or -(Z)-CH═CHCl;
• R6 is A, B, C or D wherein R11 is hydrogen or C1-3 alkyl;
• R7 is hydrogen, methyl, halomethyl or halogen;
• either
• (a) R9 is OR8b and R10 is hydrogen wherein R8a and R8b are (i) independently hydrogen, benzoyl or C1-6 acyl or (i) together R8a and R8b are C(Me)2, C(CH2)4, CHPh, or
• (b) R9 is hydrogen and R10 is OR8b wherein R8a and R8b are independently hydrogen or C1-6 acyl;
• m is 0 to 3;
• n is 4 or 5;
• p is 0 to 2;
• r is 1 to 6;
• and,
• pharmacologically acceptable salts thereof.